ReviewJournal of ovarian research2026
Interconnected cell death pathways: central mechanisms and therapeutic targets in impaired follicular development of polycystic ovary syndrome.
Review in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism and insulin resistance, which synergistically disrupt the ovarian microenvironment. This pathological interplay induces chronic inflammation, oxidative stress, and metabolic dysregulation, subsequently triggering aberrant activation of multiple forms of programmed cell death (PCD) in granulosa cells, including apoptosis, pyroptosis, necroptosis, autophagy, and ferroptosis. Recent experimental studies, mainly based on animal and in vitro models, suggest that these death pathways may be interconnected through shared regulatory hubs, forming a dynamic interactive network referred to as the ‘death crosstalk’. Inhibition of apoptosis leads to defective follicular atresia and accumulation of immature follicles; pyroptosis and necroptosis amplify inflammatory cascades, promoting ovarian fibrosis and aggravating insulin resistance; ferroptosis induces lipid peroxidation–mediated granulosa cell injury, thereby reducing follicle-stimulating hormone (FSH) sensitivity; dysregulated autophagy exacerbates ferroptosis through ferritinophagy and degradation of GPX4. Targeting key nodes of the death crosstalk network—such as the NLRP3 inflammasome, RIPK1/RIPK3, and the ferroptosis–GPX4 axis—or employing epigenetic and gene-editing interventions, potentially holds promise for overcoming the limitations of single-target therapies. Such multi-target modulation may provide novel strategies to simultaneously improve ovulatory dysfunction and metabolic complications in PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.